Experimental MDS drug trial halted early – what we know

NCT ID NCT04823624

Terminated Disease control Sponsor: Massachusetts General Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a drug called MBG453 in 10 people with a type of bone marrow disorder called lower-risk myelodysplastic syndromes (MDS). The goal was to see if the drug could improve blood cell counts and reduce the need for transfusions. The trial was terminated early, so the full results are not available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MBG453 (a monoclonal antibody)
What this could lead to: If successful, this could point toward a new treatment option for lower-risk MDS patients who have not responded to standard therapies.
What could go wrong: This was a very small, early-phase trial that was terminated early, so results are limited. The drug may not prove effective or safe in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myelodysplastic syndrome Myelodysplastic Syndromes

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYELODYSPLASTIC SYNDROMES

Contacts and locations

Locations

Brigham and Women's Hospital

Boston, Massachusetts, 02215, United States
Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Massachusetts General Hospital Cancer Center

Boston, Massachusetts, 02114, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.